Recombinant Human Interleukin-36 Receptor Antagonist Protein

Synonyms IL-1RP3, IL-1HY1, IL-1 delta, IL-1F5, IL-1ra homolog 1, IL-1L1

Accession Q9UBH0

GeneID 26525

Source Escherichia coli.

Molecular Weight Approximately 16.8 kDa, a single non-glycosylated polypeptide chain containing 154 amino acids.

Quantity 5µg/25µg/1mg

AA Sequence VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAGKVIKGEE ISVVPNRWLD ASLSPVILGV QGGSQCLSCG VGQEPTLTLE PVNIMELYLG AKESKSFTFY RRDMGLTSSF ESAAYPGWFL CTVPEADQPV RLTQLPENGG WNAPITDFYF QQCD

Purity > 95 % by SDS-PAGE and HPLC analyses.

Biological Activity Fully biologically active when compared to standard. The ED50 as determined by inhibiting IL-36 beta induced IL-8 secretion by human preadipocytes is less than 1.0 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 20 ng/ml of recombinant human IL-36 beta.

Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.

Endotoxin Less than 1 EU/µg of rHuIL-36RA as determined by LAL method.

Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.

- 1 month, 2 to 8 °C under sterile conditions after reconstitution.

- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Usage This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

SDS-PAGE

Reference 1. Born TL, Smith DE, Garka KE, et al. 2000. J Biol Chem. 275:41528.

2. Dunn EF, Gay NJ, Bristow AF, et al. 2003. Biochemistry. 42:10938-44.

3. Barton JL, Herbst R, Bosisio D, et al. 2000. Eur J Immunol. 30:3299-308.

4. Debets R, Timans JC, Homey B, et al. 2001. J Immunol. 167:1440-6.

5. Towne JE, Renshaw BR, Douangpanya J, et al. 2011. J Biol Chem. 286:42594-602.

Background Interleukin-36 receptor antagonist (IL-36RA) is a secreted protein which belongs to the interleukin 1 cytokine family (IL-1 family) and it is predominantly expressed in keratinocytes but not in fibroblasts, endothelial cells or melanocytes. IL-36RA has been reported to antagonize the biological activity of IL-36α (IL-1F6), IL-36β (IL-1F8), and IL-36γ (IL-1F9). Furthermore, it could constitute part of an independent signaling system analogous to interleukin-1 alpha (IL-1A), beta (IL-1B) receptor agonist and interleukin-1 receptor type I (IL-1R1). In addition, The receptor for IL-36RA has not been positively identified. Indirect evidence suggests it is IL-1Rrp2. Recombinant human IL-36 RA contains 154 amino acid residues and it shares 91 % a.a. sequence identity with murine IL-36RA.